{"id":"alternative-medications-carboplatin","safety":{"commonSideEffects":[{"rate":"25-35","effect":"Thrombocytopenia"},{"rate":"15-25","effect":"Neutropenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"10-15","effect":"Nausea and vomiting"},{"rate":"5-10","effect":"Nephrotoxicity"},{"rate":"5","effect":"Ototoxicity"},{"rate":"5-10","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. This leads to apoptosis in cancer cells. It is a second-generation platinum compound designed to have a more favorable toxicity profile than cisplatin while maintaining anti-tumor efficacy.","oneSentence":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:01:04.180Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Non-small cell lung cancer"},{"name":"Small cell lung cancer"},{"name":"Head and neck cancer"},{"name":"Breast cancer"},{"name":"Testicular cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07154966","phase":"","title":"Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-03-15","conditions":"Ovarian Cancer (OvCa), Fallopian Tube Cancers, Endometrial Cancer","enrollment":102},{"nctId":"NCT04838652","phase":"PHASE2","title":"Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-03-05","conditions":"Classical Hodgkin Lymphoma","enrollment":29},{"nctId":"NCT06532539","phase":"PHASE2","title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-06-13","conditions":"Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis","enrollment":30},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT06140082","phase":"","title":"Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression","status":"UNKNOWN","sponsor":"LI YAN","startDate":"2023-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":477},{"nctId":"NCT04728724","phase":"PHASE2","title":"Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-09-10","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":100},{"nctId":"NCT05772377","phase":"PHASE2","title":"Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-07-01","conditions":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","enrollment":36},{"nctId":"NCT04772001","phase":"NA","title":"Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2021-03-12","conditions":"Uterine Cervical Neoplasms, Chemoradiotherapy, Angiogenesis","enrollment":53},{"nctId":"NCT05044728","phase":"PHASE2","title":"Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-04-01","conditions":"Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT03151642","phase":"","title":"A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2017-04-05","conditions":"Esophageal Cancer","enrollment":11},{"nctId":"NCT02283424","phase":"PHASE4","title":"Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2014-10","conditions":"Neoplasms, Therapy-Associated","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":495,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Alternative medications: carboplatin","genericName":"Alternative medications: carboplatin","companyName":"Universität des Saarlandes","companyId":"universit-t-des-saarlandes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Ovarian cancer, Non-small cell lung cancer, Small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}